Adam R Glassman
Overview
Explore the profile of Adam R Glassman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
5960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Glassman A, Elmasry M, Baskin D, Brigell M, Chong V, Davis Q, et al.
Ophthalmol Sci
. 2024 Jun;
4(5):100519.
PMID: 38881606
Clinical Relevance: Visual function impairment from diabetic retinopathy can have a considerable impact on patient's quality of life. Best-corrected visual acuity (BCVA) is most commonly used to assess visual function...
3.
Jhaveri C, Liu D, Maguire M, Glassman A, Grigorian R, Jampol L, et al.
Ophthalmology
. 2024 Feb;
131(8):967-974.
PMID: 38336282
Purpose: To identify factors for meeting prespecified criteria for switching from bevacizumab to aflibercept in eyes with center-involved diabetic macular edema (CI-DME) and moderate vision loss initially treated with bevacizumab...
4.
Blinder K, Calhoun C, Maguire M, Glassman A, Mein C, Baskin D, et al.
Ophthalmol Retina
. 2023 Oct;
8(4):376-387.
PMID: 37879537
Objective: To assess the feasibility of daily Home OCT imaging among patients with neovascular age-related macular degeneration (nAMD). Design: Prospective observational study. Participants: Participants with ≥ 1 eye with previously...
5.
6.
Maturi R, Glassman A, Josic K, Baker C, Gerstenblith A, Jampol L, et al.
JAMA
. 2023 Feb;
329(5):376-385.
PMID: 36749332
Importance: Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes over at least...
7.
Hutton D, Glassman A, Liu D, Sun J
JAMA Ophthalmol
. 2023 Feb;
141(3):268-274.
PMID: 36729431
Importance: The DRCR Retina Network Protocol AC showed no significant difference in visual acuity outcomes over 2 years between treatment with aflibercept monotherapy and bevacizumab first with switching to aflibercept...
8.
Silva P, Marcus D, Liu D, Aiello L, Antoszyk A, Elman M, et al.
JAMA Ophthalmol
. 2022 Aug;
140(10):936-945.
PMID: 35980610
Importance: Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR worsening or treatment over 4 years. Whether baseline retinal...
9.
Marcus D, Silva P, Liu D, Aiello L, Antoszyk A, Elman M, et al.
JAMA Ophthalmol
. 2022 Aug;
140(10):946-954.
PMID: 35980608
Importance: Ultra-widefield (UWF) imaging improves the ability to identify peripheral diabetic retinopathy (DR) lesions compared with standard imaging. Whether detection of predominantly peripheral lesions (PPLs) better predicts rates of disease...
10.
Jhaveri C, Glassman A, Ferris 3rd F, Liu D, Maguire M, Allen J, et al.
N Engl J Med
. 2022 Jul;
387(8):692-703.
PMID: 35833805
Background: In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not...